## **Multiple Sclerosis and Pregnancy**

Maria Pia Amato University of Florence, Italy IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

### DISCLOSURES

#### MP Amato

- Has received research grants for her Department by Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Almirall, Roche, FISM, Italian Health Ministry

- Has received honoraria as a speaker and member of advisory boards by Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Roche

- Is Co-Editor of Multiple Sclerosis Journal




# Learning Objectives

After attending this educational activity, participants should be able to:

- Understand the impact of pregnancy on the disease activity in women with MS
- Learn about the safety profile and risks to the fetus and the mother with the use of different disease modifying therapies, based on the most recent evidence
- Optimize treatment strategies before, during and after pregnancy in women with MS who contemplate a pregnancy plan / become pregnant
- Understand the implications of breastfeeding and its impact on the disease activity in women with MS
- Appreciate gaps in knowledge and current challenges for women with MS who desire to become pregnant / breastfead their infant.

## IMPACT OF PREGNANCY ON MS



PRIMS. Confavreux C, et al. N Engl J Med. 1998;339:285-91

Special challenges in the new DMD era

- Management of pregnancy in patients with highly active disease
- Pregnancies occurring soon after suspension of natalizumab or fingolimod: risk of disease reactivation/rebound during pregnancy
- Unplanned pregnancies occurring while on drugs that are risky to the fetus /for which the risk is not known

### **KEY MESSAGES**

#### Proactive Counseling

- Discuss pregnancy plans /contraception at or soon after diagnosis
- Update this information at regular intervals
- Planning
  - Plan pregnancy in a stable phase of the disease (no clinical and MRI activity <u>></u>1 year)
  - Establish an *individualized treatment plan* before, during and after pregnancy, taking into account the balance between fetal risks and maternal risks
- Multidisciplinary Management
  - MS team
  - Obstetric team
  - Pharmacologist
  - Fertility expert





# References

1: Simone IL, Tortorella C, Ghirelli A. Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies. Front Neurol. 2021 Ju 1;12:697974. doi: 10.3389/fneur.2021.697974. PMID: 34276545; PMCID: PMC8280312.

2: Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S,Bove R, Cavalla P, Clerico M, Corona T, Doshi A, Fragoso Y, Jacobs D, Jokubaitis V, Landi D, Llamosa G, Longbrake EE, Maillart E, Marta M, Midaglia L, Shah S, Tintore M, van der Walt A, Voskuhl R, Wang Y, Zabad RK, Zeydan B, Houtchens M, Hellwig K. Sex effects across the lifespan in women with multiple sclerosis. Ther Adv Neurol Disord. 2020 Jul 1;13:1756286420936166. doi: 10.1177/1756286420936166. PMID: 32655689; PMCID: PMC7331774.

3: Langer-Gould AM. Pregnancy and Family Planning in Multiple Sclerosis.Continuum (Minneap Minn). 2019 Jun;25(3):773-792. doi:10.1212/CON.000000000000745. PMID: 31162316.

4: Coyle PK, Oh J, Magyari M, Oreja-Guevara C, Houtchens M. Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. Mult Scler Relat Disord. 2019 Jul;32:54-63. doi: 10.1016/j.msard.2019.04.003. Epub 2019 Apr 5. PMID: 31030020.

5: Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol. 2019 Apr;19(2):106-114. doi: 10.1136/practneurol-2018-002060. Epub 2019 Jan 5. PMID: 30612100.

6. Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of Women with Multiple Sclerosis Planning Pregnancy. Curr Treat Options Neurol. 2021;23(4):11. doi: 10.1007/s11940-021-00666-4. Epub 2021 Mar 30. PMID: 33814892; PMCID: PMC8008016.

7. Krysko KM, Rutatangwa A, Graves J, Lazar A, Waubant E. Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysis. JAMA Neurol. 2020 Mar 1;77(3):327-338. doi: 10.1001/jamaneurol.2019.4173. PMID: 31816024; PMCID: PMC6902174.